NHS Branded Medicines Framework for North of England and Midlands and East - 1 March 2024
Details
- Buyer
- NHS England
- Supplier(s)
38 suppliers
- AVENTIS PHARMA LIMITED
- Abbvie Ltd
- Accord UK Ltd
- Almirall
- Amgen Ltd
- Astra Zeneca UK Limited
- Bayer Public Limited Company
- Celltrion Healthcare United Kingdom Ltd
- Chugai Pharma UK Ltd
- CST Pharma Limited
- Dr Reddy's Laboratories (UK) Ltd
- Eli Lilly and Company Ltd
- Galapagos Biotech Ltd
- GEDEON RICHTER (UK) LIMITED
- GLAXOSMITHKLINE UK LIMITED
- Ipsen
- Janssen Cilag Ltd
- Kent Pharma Ltd
- Merck Serono Limited
- MERCK SHARP & DOHME (UK) LIMITED
- Merz
- Mylan
- Napp Pharmaceuticals Ltd
- Neon Healthcare Ltd
- Novartis Pharmaceutical UK Ltd
- Novo Nordisk Ltd
- Organon Pharmaceuticals UK Ltd
- Orifarm UK
- Pfizer Liimted
- Pharmacosmos UK Ltd
- Ranbaxy (UK) Ltd
- Roche Products Ltd
- Sandoz
- Swedish Orphan Biovitrum Ltd (Sobi UK Ltd)
- Teva UK Ltd
- Thornton and Ross
- Vifor Pharma UK Ltd
- Zentiva Pharma UK Ltd
- Value
- GBP 688,010,000
- Duration
- 3 years
- Topic
- Pharmaceutical products
- Published
- 26 February 2024
- Source
- uk:contracts_finder
Tender description
Project Title: NHS Branded Medicines Framework for North of England and Midlands and East - 1 March 2024 Offer reference number: CM/PHR/22/5678 CM/PHR/22/5678/01 - NHS Framework for NORTH OF ENGLAND Branded Medicines - Tranche B. Period of framework: 1 March 2024 to 31 August 2025 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. CM/PHR/22/5678/02 - NHS Framework for NORTH OF ENGLAND Branded Medicines (to transition to Tranche B) Period of framework: 1 March 2024 to 31 August 2025 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. CM/PHR/22/5678/03 - NHS Framework for MIDLANDS AND EAST of England Branded Medicines - Tranche A. Period of framework: 1 March 2024 to 31 August 2026 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 12 months CM/PHR/22/5678/04 - NHS Framework for MIDLANDS AND EAST of England Branded Medicines (to transition to Tranche B). Period of framework: 1 March 2024 to 31 August 2025 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 12 months
Timeline
- Completed: Award published26 February 2024Current notice
- Completed: Award date1 March 2024
- Next: Contract expiry date31 August 2026in 2 days
About the buyer
NHS England is a public sector buyer in United Kingdom publishing tenders and awards on Stotles. Explore their procurement activity and find more opportunities like this one.
Relevant CPV codes
- 33600000 · Pharmaceutical products
Decision makers
Connect with the people behind this procurement.
| Contact name | Job title | Phone number | Work email |
|---|---|---|---|
| Head of Procurement | +44 •••• •••••• | ••••••••@nhs-england.gov | |
| Commercial Director | +44 •••• •••••• | ••••••••@nhs-england.gov | |
| Procurement Manager | +44 •••• •••••• | ••••••••@nhs-england.gov | |
| Category Lead | +44 •••• •••••• | ••••••••@nhs-england.gov | |
| Senior Buyer | +44 •••• •••••• | ••••••••@nhs-england.gov | |
| Contracts Manager | +44 •••• •••••• | ••••••••@nhs-england.gov |
6 similar open tenders
See more open tenders related to NHS Branded Medicines Framework for North of England and Midlands and East - 1 March 2024.
- Open tender
IMP Manufacture, Labelling and Packaging DPS
- Open tender
CPH037 - Enhanced Services (Pharmacies)
- Open tender
Potassium iodide tablets 2024-2026
Related buyers
Buyers similar to NHS England.
- 461£2.1bn
- 372£250.0m
- 362£15.0bn
- 294£2.8bn
- 267£19.9bn
- 263£902.6m
- 250£511.2m
- 203£1.0bn
- 142£900.0m
- 122£59.9m
Win more public sector contracts
Track every UK and Ireland tender in one place — set up alerts, find decision-makers, and never miss an opportunity.
